Biotech entity
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention Organogenesis, the most common co-covered peer. We currently track 1 Biotech story that mention Docebo, all published on March 8, 2026. Each carries 3 original sources on average.
Last mentioned: Mar 8, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention Organogenesis, the most common co-covered peer. We currently track 1 Biotech story that mention Docebo, all published on March 8, 2026. Each carries 3 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 10 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Docebo. Shared-story counts are live from our verified record — not editorial picks.
Wall Street Zen has upgraded Organogenesis (NASDAQ: ORGO) to a 'Buy' rating, signaling increased confidence in the regenerative medicine specialist's market position. This move comes amid a broader wave of optimistic re-ratings for mid-cap growth stocks across multiple sectors, including oilfield services and software.
Docebo is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
